Literature DB >> 35397080

Clinical trial data and emerging strategies: HER2-positive breast cancer.

Sonia Pernas1,2, Sara M Tolaney3,4.   

Abstract

A deeper insight into tumor biology and HER2 signaling has led to the development of novel anti-HER2 drugs that have significantly improved the prognosis of patients with HER2-positive breast cancer. The breast cancer immune microenvironment has emerged as a potential prognostic factor. Moreover, the host immune system not only seems to play a critical role in the prognosis of HER2-positive breast cancer, but also seems to modulate treatment response to some HER2-targeted agents. Here, we review the latest evidence of the role of immunotherapy in HER2-positive breast cancer and present emerging strategies.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Antibody-dependent cellular cytotoxicity; HER2-positive breast cancer; Immune checkpoints; Immunotherapy; Tumor immune microenvironment; Tumor-infiltrating lymphocytes

Mesh：

Substances：

Year:  2022        PMID： 35397080     DOI： 10.1007/s10549-022-06575-7

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN： 0167-6806            Impact factor:   4.872


  41 in total

1.  Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Miguel Martin; Frankie A Holmes; Bent Ejlertsen; Suzette Delaloge; Beverly Moy; Hiroji Iwata; Gunter von Minckwitz; Stephen K L Chia; Janine Mansi; Carlos H Barrios; Michael Gnant; Zorica Tomašević; Neelima Denduluri; Robert Šeparović; Erhan Gokmen; Anna Bashford; Manuel Ruiz Borrego; Sung-Bae Kim; Erik Hugger Jakobsen; Audrone Ciceniene; Kenichi Inoue; Friedrich Overkamp; Joan B Heijns; Anne C Armstrong; John S Link; Anil Abraham Joy; Richard Bryce; Alvin Wong; Susan Moran; Bin Yao; Feng Xu; Alan Auerbach; Marc Buyse; Arlene Chan
Journal:  Lancet Oncol       Date:  2017-11-13       Impact factor: 41.316

2.  Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.

Authors:  Carsten Denkert; Gunter von Minckwitz; Silvia Darb-Esfahani; Bianca Lederer; Barbara I Heppner; Karsten E Weber; Jan Budczies; Jens Huober; Frederick Klauschen; Jenny Furlanetto; Wolfgang D Schmitt; Jens-Uwe Blohmer; Thomas Karn; Berit M Pfitzner; Sherko Kümmel; Knut Engels; Andreas Schneeweiss; Arndt Hartmann; Aurelia Noske; Peter A Fasching; Christian Jackisch; Marion van Mackelenbergh; Peter Sinn; Christian Schem; Claus Hanusch; Michael Untch; Sibylle Loibl
Journal:  Lancet Oncol       Date:  2017-12-07       Impact factor: 41.316

3.  Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.

Authors:  Luca Gianni; Tadeusz Pienkowski; Young-Hyuck Im; Laslo Roman; Ling-Ming Tseng; Mei-Ching Liu; Ana Lluch; Elżbieta Staroslawska; Juan de la Haba-Rodriguez; Seock-Ah Im; Jose Luiz Pedrini; Brigitte Poirier; Paolo Morandi; Vladimir Semiglazov; Vichien Srimuninnimit; Giulia Bianchi; Tania Szado; Jayantha Ratnayake; Graham Ross; Pinuccia Valagussa
Journal:  Lancet Oncol       Date:  2011-12-06       Impact factor: 41.316

4.  A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade.

Authors:  P Nuciforo; T Pascual; J Cortés; A Llombart-Cussac; R Fasani; L Paré; M Oliveira; P Galvan; N Martínez; B Bermejo; M Vidal; S Pernas; R López; M Muñoz; I Garau; L Manso; J Alarcón; E Martínez; V Rodrik-Outmezguine; J C Brase; P Villagrasa; A Prat; E Holgado
Journal:  Ann Oncol       Date:  2018-01-01       Impact factor: 32.976

5.  Targeting HER2 heterogeneity in early-stage breast cancer.

Authors:  Sonia Pernas; Sara M Tolaney
Journal:  Curr Opin Oncol       Date:  2020-11       Impact factor: 3.645

6.  Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.

Authors:  Shanu Modi; Cristina Saura; Toshinari Yamashita; Yeon Hee Park; Sung-Bae Kim; Kenji Tamura; Fabrice Andre; Hiroji Iwata; Yoshinori Ito; Junji Tsurutani; Joohyuk Sohn; Neelima Denduluri; Christophe Perrin; Kenjiro Aogi; Eriko Tokunaga; Seock-Ah Im; Keun Seok Lee; Sara A Hurvitz; Javier Cortes; Caleb Lee; Shuquan Chen; Lin Zhang; Javad Shahidi; Antoine Yver; Ian Krop
Journal:  N Engl J Med       Date:  2019-12-11       Impact factor: 91.245

7.  Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.

Authors:  Rashmi K Murthy; Sherene Loi; Alicia Okines; Elisavet Paplomata; Erika Hamilton; Sara A Hurvitz; Nancy U Lin; Virginia Borges; Vandana Abramson; Carey Anders; Philippe L Bedard; Mafalda Oliveira; Erik Jakobsen; Thomas Bachelot; Shlomit S Shachar; Volkmar Müller; Sofia Braga; Francois P Duhoux; Richard Greil; David Cameron; Lisa A Carey; Giuseppe Curigliano; Karen Gelmon; Gabriel Hortobagyi; Ian Krop; Sibylle Loibl; Mark Pegram; Dennis Slamon; M Corinna Palanca-Wessels; Luke Walker; Wentao Feng; Eric P Winer
Journal:  N Engl J Med       Date:  2019-12-11       Impact factor: 91.245

Review 8.  Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer.

Authors:  Gaia Griguolo; Tomás Pascual; Maria Vittoria Dieci; Valentina Guarneri; Aleix Prat
Journal:  J Immunother Cancer       Date:  2019-03-29       Impact factor: 13.751

Review 9.  Immune Infiltrates in Breast Cancer: Recent Updates and Clinical Implications.

Authors:  Maria Vittoria Dieci; Federica Miglietta; Valentina Guarneri
Journal:  Cells       Date:  2021-01-23       Impact factor: 6.600

10.  Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial.

Authors:  Cristina Saura; Mafalda Oliveira; Yin-Hsun Feng; Ming-Shen Dai; Shang-Wen Chen; Sara A Hurvitz; Sung-Bae Kim; Beverly Moy; Suzette Delaloge; William Gradishar; Norikazu Masuda; Marketa Palacova; Maureen E Trudeau; Johanna Mattson; Yoon Sim Yap; Ming-Feng Hou; Michelino De Laurentiis; Yu-Min Yeh; Hong-Tai Chang; Thomas Yau; Hans Wildiers; Barbara Haley; Daniele Fagnani; Yen-Shen Lu; John Crown; Johnson Lin; Masato Takahashi; Toshimi Takano; Miki Yamaguchi; Takaaki Fujii; Bin Yao; Judith Bebchuk; Kiana Keyvanjah; Richard Bryce; Adam Brufsky
Journal:  J Clin Oncol       Date:  2020-07-17       Impact factor: 44.544
View more
  1 in total

1.  Efficacy and safety of neoadjuvant pyrotinib plus docetaxel/liposomal doxorubicin/cyclophosphamide for HER2-positive breast cancer.

Authors:  Chunyu Tian; Minghui Wang; Hancheng Liu; Jianping Liu; Mengze Xu; Lihui Ma
Journal:  Ir J Med Sci       Date:  2022-07-13       Impact factor: 2.089
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.